Published in Hepatitis Weekly, December 9th, 2002
Patients treated with Infergen in combination with ribavirin achieved a higher sustained virologic response (SVR), the study's primary endpoint, compared with those patients treated with Rebetron.
"These data suggest...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly